Cargando…
Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen
The CAALA (Complex Augmentation of ALA) regimen was developed with the goal of redressing some of the weaknesses of 5-aminolevulinic acid (5-ALA) use in glioblastoma treatment as it now stands. 5-ALA is approved for use prior to glioblastoma surgery to better demarcate tumor from brain tissue. 5-ALA...
Autores principales: | Kast, Richard E., Skuli, Nicolas, Sardi, Iacopo, Capanni, Felix, Hessling, Martin, Frosina, Guido, Kast, Anton P., Karpel-Massler, Georg, Halatsch, Marc-Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315943/ https://www.ncbi.nlm.nih.gov/pubmed/30469467 http://dx.doi.org/10.3390/brainsci8120203 |
Ejemplares similares
-
Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen
por: Kast, Richard E, et al.
Publicado: (2017) -
A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen
por: Kast, Richard E., et al.
Publicado: (2020) -
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
por: Kast, Richard E., et al.
Publicado: (2014) -
The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy
por: Kast, Richard E, et al.
Publicado: (2017) -
Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
por: Pala, Andrej, et al.
Publicado: (2012)